Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Mark G. Foletta to Board of Directors

On June 29, 2020, the Board of Directors of Enanta Pharmaceuticals, Inc. announced that Mark G. Foletta had been elected to serve as an independent director of the company in the class of directors whose terms expire at Enanta's 2022 annual meeting of stockholders. This election increases the number of directors to seven. The Board of Directors also appointed Mr. Foletta to be Chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee of the Board of Directors. Mr. Foletta will receive the standard cash compensation for non-employee directors of Enanta, including retainer fees for Board and committee service. In addition, he received a stock option to purchase 17,000 shares of Enanta's Common Stock, which will vest over 36 months. Mr. Foletta will also have the benefit of Enanta's standard form of indemnification agreement for non-employee directors.


                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses